Tag: carcinoid treatments

Carcinoid Cancer Foundation Releases New Video Series Beginning with “The ABC’s of Carcinoid/NETs”

What is the most common kind of neuroendocrine tumor (NET)?  How do these tumors grow?  What is carcinoid syndrome?  What are the quality of life issues for patients?  In “The ABC’s of Carcinoid/NETs,” three of the world’s leading carcinoid and NET cancer…

FDA Approves Amendment for PRRT Clinical Trial in Texas

BREAKING NEWS:  The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate…

Phase II Clinical Trial Recruiting Carcinoid and Related Neuroendocrine Tumor Patients

Participants are being recruited for a Phase II clinical study of capecitabine and temozolomide (CAPTEM) for neuroendocrine cancer patients with progressive, differentiated, metastatic neuroendocrine tumors (NETs). Patients with carcinoid,…

Carcinoid Cancer Foundation’s May 2011 Symposium Now Online

The Carcinoid Cancer Foundation is pleased to share with you videos from its carcinoid/NET symposium, “Neuroendocrine Tumor Management:  The Era of Personalized Medicine,” held on May 1, 2011 at Mt. Sinai Medical Center in New York City.

Following …

Up-to-the-Minute: News for the Carcinoid and Neuroendocrine Tumor Community

The first device that simultaneously performs PET and MRI scans, a new alpha-emitter-based therapy for NET cancer patients with progressive therapy-resistant tumors, the first–ever randomized virtual clinical trial, over 100  abstracts on carcinoid…

Breaking News: FDA Approves Treatment for pNET Patients

For the first time in nearly three decades, there is a new treatment for pancreatic neuroendocrine tumor patients!  The Food and Drug Administration (FDA) today announced its approval of Afinitor© for pNET patients.  This is a milestone for the carcinoid/NET…

Carcinoid Cancer Foundation Thanks Symposium Sponsors

There’s still time to register for the Carcinoid Cancer Foundation’s 14th annual  symposium for patients, family, friends, and healthcare professionals, which will be held on Sunday, May 1st at Mount Sinai Medical Center in New York City.  The Foundation…

RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients

Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund.  According to Ebrahim…

WebMD Articles Raise Awareness about Carcinoid Cancer

Understanding carcinoid tumors, carcinoid syndrome, and treatments for carcinoid when surgery is not an option are the focus of three feature articles by Ellen Greenlaw on WebMD.com this month.  For these articles, Ms. Greenlaw sought the expertise…

A Carcinoid Soldier’s Survivor Story

When Staff Sergeant Daniel Barber of D Company 1-106th AVN in the Missouri National Guard was first diagnosed with carcinoid cancer in 2009 he experienced feelings of shock, despair, anger, fear and frustration.  But he was also relieved because he knew…